Candel Therapeutics gains on FDA's 'fast track' tag for cancer therapy

Candel Therapeutics

12/12/2023 13:53

** Shares of cancer therapy developer Candel Therapeutics
 CADL.O  rise 55.44% to $1.35 premarket
    ** Co says the U.S. FDA has granted a "fast track" tag to
its lead investigational therapy CAN-2409, for the treatment of
a type of pancreatic cancer
    ** FDA's "fast track" status expedites the review of drug
candidates being developed to treat serious conditions
    ** Candel remains on track to release updated overall
survival data from the interim analysis of a mid-stage trial in
H2 2024
    ** Up to last close, stock down ~52% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))